Collection
SGLT2 Inhibitors
- Submission status
- Closed
This special series of reviews focuses on the newest class of glucose-lowering agents, the sodium–glucose cotransporter (SGLT) inhibitors. Rieg and Vallon begin the series by tracing the development of the SGLT inhibitor class of drugs, including SGLT1 inhibitors, SGLT2 inhibitors and dual inhibitors. Wright and colleagues go on to discuss the mechanisms of actions of these drugs; they explain that SGLT1 and SGLT2 (and GLUT2) are key players in renal glucose transport and describe how inhibition of either SGLT2 or SGLT1 promotes glucose excretion in the urine. However, as discussed by Thomas and Cherney, SGLT inhibitors not only affect glucose metabolism, but also adiposity, renal function and blood pressure in type 2 diabetes. In terms of their pleiotropic actions, the most striking results so far come from SGLT2 inhibitor studies investigating the cardiovascular effects of these drugs. In their review, Verma and McMurray outline the proposed mechanisms underpinning the unprecedented benefit of reduced cardiovascular disease risk with SGLT2 inhibitor use, observed in people with type 2 diabetes with established cardiovascular disease or multiple cardiovascular risk factors. Despite their glucose-lowering ability, pleiotropic effects and potential cardioprotective outcomes, the place of SGLT2 inhibitors in the management of type 2 diabetes is still hotly debated. To explain why, Lupsa and Inzucchi review the benefits and adverse effects of SGLT2 inhibitors approved for use in the USA and Europe in individuals with type 2 diabetes. What about individuals with type 1 diabetes? Research is much sparser in this area but McCrimmon and Henry discuss the results of two recent 24 week Phase III randomised controlled clinical trials, inTandem3 and DEPICT-1, which studied sotagliflozin (a dual SGLT1/2 inhibitor) and dapagliflozin (an SGLT2 inhibitor), respectively. Wanner and Marx conclude the series by discussing SGLT2 inhibitors in the context of the future of diabetes therapy. They also discuss the effects of SGLT2 inhibitors on other chronic diseases and outline future treatment strategies.
Articles (8 in this collection)
-
-
SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases
Authors
- Christoph Wanner
- Nikolaus Marx
- Content type: Review
- Published: 22 August 2018
- Pages: 2134 - 2139
-
Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2
Authors
- Chiara Ghezzi
- Donald D. F. Loo
- Ernest M. Wright
- Content type: Review
- Open Access
- Published: 22 August 2018
- Pages: 2087 - 2097
-
Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits
Authors
- Beatrice C. Lupsa
- Silvio E. Inzucchi
- Content type: Review
- Published: 22 August 2018
- Pages: 2118 - 2125
-
SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
Authors
- Subodh Verma
- John J. V. McMurray
- Content type: Review
- Published: 22 August 2018
- Pages: 2108 - 2117
-
Development of SGLT1 and SGLT2 inhibitors
Authors
- Timo Rieg
- Volker Vallon
- Content type: Review
- Published: 22 August 2018
- Pages: 2079 - 2086
-
The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure
Authors
- Merlin C. Thomas
- David Z. I. Cherney
- Content type: Review
- Published: 22 August 2018
- Pages: 2098 - 2107
-
SGLT inhibitor adjunct therapy in type 1 diabetes
Authors
- Rory J. McCrimmon
- Robert R. Henry
- Content type: Review
- Open Access
- Published: 22 August 2018
- Pages: 2126 - 2133